Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC
Cell Biochemistry and Function · 2026-04 · 44 (4)
DOI: 10.1002/cbf.70201 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Function, online erschienen am 27.03.2026. Verfasst von Fatih Çöllü und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biology Section, Department of Biology, Faculty of Engineering and Natural Sciences, Manisa Celal Bayar University, Yunusemre-Manisa, Turke…. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Manisa Celal Bayar University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Multidrug resistance (MDR) remains a major challenge in small cell lung cancer (SCLC), limiting the efficacy of chemotherapeutics like doxorubicin. This study investigates whether silencing cellular prion protein (PrP), a known MDR‐associated molecule, can enhance doxorubicin‐induced cell death in Adriamycin‐resistant H69AR cells. Quantitative RT‐PCR and immunocytochemistry were used to assess the expression of PRNP , CD44 , BAX , and BECN1 under various treatment conditions, including doxorubicin exposure and PrP knockdown via siRNA. Autophagic activity was evaluated using monodansylcadaverine (MDC) staining. PrP knockdown significantly reduced PRNP expression and modulated CD44 mRNA levels, especially during doxorubicin co‐treatment. However, CD44 protein levels remained unchanged, suggesting post‐transcriptional regulation. BAX expression increased with doxorubicin and siRNA individually, but not in combination, indicating a PrP‐independent mechanism. BECN1 expression and Beclin‐1 protein levels were significantly elevated in all treatment groups, especially in siRNA/doxorubicin combination. MDC staining confirmed increased autophagic vacuole formation in this group, indicating activation of Beclin‐1‐mediated autophagy. In conclusion, PrP knockdown may sensitize resistant SCLC cells to doxorubicin and promote autophagy. These findings support PrP silencing as a promising strategy to reverse chemoresistance in SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Biology Section, Department of Biology, Faculty of Engineering and Natural Sciences, Manisa Celal Bayar University, Yunusemre-Manisa, Turkey.
ORCID-Profile: Fatih Çöllü, Hayrettin Kadinşah, Zübeyde Öztel, Berrin Tuğrul, Erdal Balcan
Förderung
- Manisa Celal Bayar University Scientific Research Projects Coordination Unit
Zitieren
APA
Çöllü, F., Kadinşah, H., Öztel, Z., Tuğrul, B., & Balcan, E. (2026). Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC. Cell Biochemistry and Function, 44(4). https://doi.org/10.1002/cbf.70201
Vancouver
Çöllü F, Kadinşah H, Öztel Z, Tuğrul B, Balcan E. Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC. Cell Biochemistry and Function. 2026;44(4). doi:10.1002/cbf.70201
BibTeX
@article{ll2026,
author = {Çöllü, Fatih and Kadinşah, Hayrettin and Öztel, Zübeyde and Tuğrul, Berrin and Balcan, Erdal},
title = {Targeting Prion Protein to Overcome Doxorubicin Resistance in SCLC},
journal = {Cell Biochemistry and Function},
year = {2026},
volume = {44},
number = {4},
doi = {10.1002/cbf.70201}
}
EUVIMED